Skip to main content
. 2014 Jun 21;11:115. doi: 10.1186/1742-2094-11-115

Figure 2.

Figure 2

Glimepiride reduces cytokine secretion from RAW 264 cells incubated with PrP82-146. (A) The concentrations of TNF produced by RAW 264 cells incubated with PrP82-146 (●), PrP82-146scrambled (■) or PrP82-146 and 1 μg/ml polymyxin B (□). Values are means ± SD from triplicate experiments performed 4 times, n = 12. (B) The concentrations of TNF produced by RAW 264 cells pre-treated with control medium (●), 5 μM glimepiride (○) or 5 μM glipizide (□) and incubated with PrP82-146. Values are means ± SD from triplicate experiments performed 4 times, n = 12. (C) There was a significant correlation between the amounts of cellular CD14 of RAW 264 cells treated with glimepiride (0.3 to 5 μM) for 1 hour and TNF production after the addition of 50 μM PrP82-146, Pearson’s coefficient = 0.858, P < 0.01. (D) The concentrations of IL-1β produced by RAW 264 cells pre-treated with control medium (●), 5 μM glimepiride (○) or 5 μM glipizide (□) and incubated with PrP82-146. Values are means ± SD from triplicate experiments performed 4 times, n = 12. (E) The concentrations of IL-6 produced by RAW 264 cells pre-treated with control medium (●), 5 μM glimepiride (○) or 5 μM glipizide (□) and incubated with PrP82-146. Values are means ± SD from triplicate experiments performed 4 times, n = 12.